{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T09:26:13Z","timestamp":1793957173754,"version":"4.8.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.atherosclerosis.2023.04.013","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T16:40:33Z","timestamp":1683823233000},"page":"38-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain"],"prefix":"10.1016","volume":"375","author":[{"given":"Juan","family":"Cos\u00edn-Sales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Campuzano Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"D\u00edaz D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5584-4735","authenticated-orcid":false,"given":"Carlos","family":"Escobar Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Rosa","family":"Fern\u00e1ndez Olmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"G\u00f3mez-Doblas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Mostaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Pedro-Botet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Plana Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Valdivielso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib1","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","article-title":"Heart disease and stroke statistics-2022 update: a report from the American heart association","volume":"145","author":"Tsao","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC Scientific Document Group. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib3","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012924","article-title":"Cholesterol and atherosclerotic cardiovascular disease: a lifelong problem","volume":"8","author":"Gidding","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib5","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib6","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jama.2018.2426","article-title":"Lipid lowering in acute coronary syndrome: is treatment early enough?","volume":"319","author":"Nicholls","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib7","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.recesp.2021.04.015","article-title":"Primary prevention. The cornerstone to reduce the burden of cardiovascular disease","volume":"74","author":"Barrios","year":"2021","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.recesp.2019.07.024","article-title":"Recommendations to improve lipid control. Consensus document of the Spanish Society of Cardiology","volume":"73","author":"Escobar","year":"2020","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib9","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.rccl.2021.05.002","article-title":"Recommendations to improve lipid control in primary prevention patients. A consensus document of the Spanish Society of Cardiology","volume":"56","author":"Barrios","year":"2021","journal-title":"REC. CardioClinics."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib10","first-page":"879","article-title":"An innovative lipid-lowering approach to enhance attainment of low-density lipoprotein cholesterol goals","volume":"9","author":"Buonvino","year":"2020","journal-title":"Eur. Heart. J. Acute. Cardiovasc. Care."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105499","article-title":"Optimal use of lipid-lowering therapy after acute coronary syndromes: a Position Paper endorsed by the International Lipid Expert Panel (ILEP)","volume":"166","author":"Banach","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.recesp.2010.11.005","article-title":"Cardiovascular risk factors in Spain in the first decade of the 21st century, a pooled analysis with individual data from 11 population-based studies: the DARIOS study","volume":"64","author":"Grau","year":"2011","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.arteri.2013.07.006","article-title":"Achievement of low-density lipoprotein cholesterol therapeutic goal in lipid and vascular risk units of the Spanish Arteriosclerosis Society","volume":"25","author":"Pedro-Botet","year":"2013","journal-title":"Cl\u00edn. Invest. Arterioscler."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib14","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.recesp.2016.02.013","article-title":"Degree of lipid control in patients with coronary heart disease and measures adopted by physicians","volume":"69","author":"Galve","year":"2016","journal-title":"REPAR study, Rev. Esp. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/2150132720946949","article-title":"Prior use of medication for primary prevention in patients with coronary syndrome","volume":"11","author":"Gaviria-Mendoza","year":"2020","journal-title":"J. Prim. Care. Community. Health"},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib16","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib17","first-page":"194","article-title":"Control of LDL-C levels after an acute coronary syndrome in Spain. Are the available treatments adequately used?","volume":"74","author":"Anguita","year":"2021","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1186\/s12916-020-01792-7","article-title":"LDL-C: lower is better for longer-even at low risk","volume":"18","author":"Penson","year":"2020","journal-title":"BMC Med."},{"issue":"Suppl 1","key":"10.1016\/j.atherosclerosis.2023.04.013_bib19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.arteri.2020.12.003","article-title":"Main barriers in the management of dyslipidaemias: intolerants","volume":"33","author":"Mostaza","year":"2021","journal-title":"Cl\u00edn. Invest. Arterioscler."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib20","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/j.1742-1241.2007.01420.x","article-title":"A global survey of physicians' perceptions on cholesterol management: the from the Heart study","volume":"61","author":"Erhardt","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib21","first-page":"177","article-title":"Barriers to cardiovascular risk prevention and management in Germany--an analysis of the EURIKA study","volume":"8","author":"Schmieder","year":"2012","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib22","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.arteri.2022.02.001","article-title":"Dyslipidemia observatory: treatment of hypercholesterolemia in Spain, context and levers for improvement in clinical practice","volume":"34","author":"Cos\u00edn-Sales","year":"2022","journal-title":"Cl\u00edn. Invest. Arterioscler."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib23","first-page":"599","article-title":"Evaluation of perceptions, knowledge and compliance with guidelines in real-life practice: a survey on the under-treatment of hypercholesterolemia","volume":"47","author":"Do\u011fan","year":"2019","journal-title":"Turk Kardiyol. Dernegi Arsivi"},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ijcp.13358","article-title":"The reasons of poor lipid target attainment for secondary prevention in real life practice: results from EPHESUS","volume":"73","author":"Mert","year":"2019","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib25","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1093\/eurjpc\/zwaa073","article-title":"Half of patients with type 2 diabetes mellitus are at very high cardiovascular risk according to the ESC\/EASD: data from a large Mediterranean population","volume":"28","author":"Cebri\u00e1n-Cuenca","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib26","doi-asserted-by":"crossref","first-page":"e1162","DOI":"10.1161\/CIR.0000000000000638","article-title":"Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American heart association and American college of cardiology","volume":"139","author":"Lloyd-Jones","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.recesp.2010.10.030","article-title":"Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain","volume":"64","author":"Gonz\u00e1lez-Juanatey","year":"2011","journal-title":"DYSIS-Spain Study, Rev. Esp. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib28","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/eurheartj\/ehr080","article-title":"Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study","volume":"32","author":"Banegas","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017817","article-title":"An enquiry based on a standardised questionnaire into knowledge, awareness and preferences concerning the care of familial hypercholesterolaemia among primary care physicians in the Asia-Pacific region: the \"Ten Countries Study\"","volume":"7","author":"Pang","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib30","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.3390\/jcm11164701","article-title":"Management of high-risk hypercholesterolemic patients and PCSK9 inhibitors reimbursement policies: data from a cohort of Italian hypercholesterolemic outpatients","volume":"11","author":"Fogacci","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib31","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020893","article-title":"What do US physicians and patients think about lipid-lowering therapy and goals of treatment? Results from the GOULD registry","volume":"10","author":"Arnold","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib32","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13528","article-title":"Management of LDL-cholesterol levels in patients with diabetes mellitus in cardiology practice: real-life evidence of under-treatment from the EPHESUS registry","volume":"51","author":"Mert","year":"2021","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib33","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib34","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.atherosclerosis.2017.06.006","article-title":"Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management","volume":"263","author":"Mancini","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib35","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.5551\/jat.24158","article-title":"The association between low-density lipoprotein cholesterol goal attainment, physician and patient attitudes and perceptions, and healthcare policy","volume":"21","author":"Wang","year":"2014","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib36","doi-asserted-by":"crossref","first-page":"628","DOI":"10.4093\/dmj.2011.35.6.628","article-title":"Low density lipoprotein cholesterol target goal attainment rate and physician perceptions about target goal achievement in Korean patients with diabetes","volume":"35","author":"Hwang","year":"2011","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib37","first-page":"434","article-title":"Clinical characteristics and unmet need among patients with atherosclerotic cardiovascular disease stratified by statin use","volume":"9","author":"Huang","year":"2016","journal-title":"Am. Health. Drug. Benefits."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib38","first-page":"156","article-title":"Determinants of treatment modification in hypercholesterolemic patients","volume":"33","author":"Wang","year":"2017","journal-title":"Acta Cardiol. Sin."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.atherosclerosis.2022.11.020","article-title":"Use of Lipoprotein(a) to improve diagnosis and management in clinical familial hypercholesterolemia","volume":"365","author":"Tromp","year":"2023","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib40","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"issue":"Supl C","key":"10.1016\/j.atherosclerosis.2023.04.013_bib41","first-page":"1","article-title":"Use of bempedoic acid in patients with dyslipidemia. A practical approach","volume":"21","author":"Escobar","year":"2021","journal-title":"Rev. Esp. Cardiol. Supl"},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib42","first-page":"847","article-title":"Which patients could benefit from the use of bempedoic acid in clinical practice?","volume":"75","author":"Barrios","year":"2022","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib43","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgad153","article-title":"Approach to the patient with a suboptimal statin response: causes and algorithm for clinical management","author":"Sun","year":"2023","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2023.04.013_bib44","doi-asserted-by":"crossref","DOI":"10.1007\/s00392-022-02147-3","article-title":"Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction (\"Jena auf Ziel\")","author":"Makhmudova","year":"2023","journal-title":"Clin. Res. Cardiol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915023001831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915023001831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:51:55Z","timestamp":1758156715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915023001831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":44,"alternative-id":["S0021915023001831"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.04.013","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of physician's perception about LDL cholesterol control in clinical practice when treating patients in Spain","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}